UNIGE document Scientific Article - Review
previous document  unige:149111  next document
add to browser collection

Mineralocorticoid receptor antagonists in patients with chronic kidney disease

Published in Pharmacology & Therapeutics. 2021, vol. 219, p. 107701
Abstract Mineralocorticoid receptor antagonists (MRA) can reduce cardiovascular morbidity and mortality in patients with heart failure and ischemic heart disease. In addition, these agents have been used in patients with diabetic nephropathy to control proteinuria and slow down chronic kidney disease (CKD) progression. Current guidelines recommend against the use of MRAs in patients with advanced CKD. However, there is growing interest on their use in this population that has unmet needs (high cardiovascular morbidity and mortality) and unique challenges (risk of acute kidney injury or hyperkalemia). This narrative review discusses the emerging role of MRAs for the management of cardiovascular disease and/or the prevention of CKD progression, highlighting results from randomized controlled trials and presenting real-world data from available registries. Results from recent trials in patients on maintenance dialysis are also discussed.
Keywords Mineralocorticoid receptor antagonistChronic kidney diseaseCongestive heart failureDiabetic nephropathyEnd-Stage renal diseaseChronic kidney disease progression
PMID: 33027644
Full text
Research group Groupe Perrier Arnaud (Médecine interne générale, de réhabilitation et de gériatrie) (585)
(ISO format)
COSIMATO, Cosimo, AGORITSAS, Thomas, MAVRAKANAS, Thomas. Mineralocorticoid receptor antagonists in patients with chronic kidney disease. In: Pharmacology & Therapeutics, 2021, vol. 219, p. 107701. doi: 10.1016/j.pharmthera.2020.107701 https://archive-ouverte.unige.ch/unige:149111

36 hits



Deposited on : 2021-02-12

Export document
Format :
Citation style :